|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Llovet JM, Zucman-Rossi J, Pikarsky E,
Sangro B, Schwartz M, Sherman M and Gores G: Hepatocellular
carcinoma. Nat Rev Dis Primers. 2:160182016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Llovet JM, Kelley RK, Villanueva A, Singal
AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J and
Finn RS: Hepatocellular carcinoma. Nat Rev Dis Primers. 7:62021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Enchev RI, Schulman BA and Peter M:
Protein neddylation: Beyond cullin-RING ligases. Nat Rev Mol Cell
Biol. 16:30–44. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu Q, Jiang Y and Sun Y: Anticancer drug
discovery by targeting cullin neddylation. Acta Pharm Sin B.
10:746–765. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhou L, Zhang W, Sun Y and Jia L: Protein
neddylation and its alterations in human cancers for targeted
therapy. Cell Signal. 44:92–102. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Soucy TA, Smith PG, Milhollen MA, Berger
AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP,
Critchley S, et al: An inhibitor of NEDD8-activating enzyme as a
new approach to treat cancer. Nature. 458:732–736. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D,
Pan Y, Ding C, Qian J, Wu L, et al: The Nedd8-activating enzyme
inhibitor MLN4924 induces autophagy and apoptosis to suppress liver
cancer cell growth. Cancer Res. 72:3360–3371. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Soucy TA, Dick LR, Smith PG, Milhollen MA
and Brownell JE: The NEDD8 conjugation pathway and its relevance in
cancer biology and therapy. Genes Cancer. 1:708–716. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Milhollen MA, Traore T, Adams-Duffy J,
Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E,
Langston SP, et al: MLN4924, a NEDD8-activating enzyme inhibitor,
is active in diffuse large B-cell lymphoma models: Rationale for
treatment of NF-{kappa}B-dependent lymphoma. Blood. 116:1515–1523.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sarantopoulos J, Shapiro GI, Cohen RB,
Clark JW, Kauh JS, Weiss GJ, Cleary JM, Mahalingam D, Pickard MD,
Faessel HM, et al: Phase I study of the investigational
NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in
patients with advanced solid tumors. Clin Cancer Res. 22:847–857.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou Q, Li H, Li Y, Tan M, Fan S, Cao C,
Meng F, Zhu L, Zhao L, Guan MX, et al: Inhibiting neddylation
modification alters mitochondrial morphology and reprograms energy
metabolism in cancer cells. JCI Insight. 4:e1215822019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ferdosi SR, Taylor B, Lee M, Tang N, Peng
S, Bybee R, Reid G, Hartman L, Garcia-Mansfield K, Sharma R, et al:
PTEN loss drives resistance to the neddylation inhibitor MLN4924 in
glioblastoma and can be overcome with TOP2A inhibitors. Neuro
Oncol. 19:noac0672022. View Article : Google Scholar
|
|
17
|
Taniguchi K and Karin M: NF-κB,
inflammation, immunity and cancer: Coming of age. Nat Rev Immunol.
18:309–324. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Elsharkawy AM and Mann DA: Nuclear
factor-kappaB and the hepatic inflammation-fibrosis-cancer axis.
Hepatology. 46:590–597. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shostak K, Zhang X, Hubert P, Göktuna SI,
Jiang Z, Klevernic I, Hildebrand J, Roncarati P, Hennuy B, Ladang
A, et al: NF-κB-induced KIAA1199 promotes survival through EGFR
signalling. Nat Commun. 5:52322014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen CY, Chang JT, Ho YF and Shyu AB:
MiR-26 down-regulates TNF-α/NF-κB signalling and IL-6 expression by
silencing HMGA1 and MALT1. Nucleic Acids Res. 44:3772–3787. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hoffmann A, Levchenko A, Scott ML and
Baltimore D: The IkappaB-NF-kappaB signaling module: Temporal
control and selective gene activation. Science. 298:1241–1245.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu B, Sun L, Liu Q, Gong C, Yao Y, Lv X,
Lin L, Yao H, Su F, Li D, et al: A cytoplasmic NF-κB interacting
long noncoding RNA blocks IκB phosphorylation and suppresses breast
cancer metastasis. Cancer Cell. 27:370–381. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ataie-Kachoie P, Badar S, Morris DL and
Pourgholami MH: Minocycline targets the NF-κB Nexus through
suppression of TGF-β1-TAK1-IκB signaling in ovarian cancer. Mol
Cancer Res. 11:1279–1291. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cao L, Zhu S, Lu H, Soutto M, Bhat N, Chen
Z, Peng D, Lin J, Lu J, Li P, et al: Helicobacter pylori-induced
RASAL2 through activation of nuclear factor-κB promotes gastric
tumorigenesis via beta-catenin signaling axis. Gastroenterology.
162:1716–1731. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lu YX, Ju HQ, Wang F, Chen LZ, Wu QN,
Sheng H, Mo HY, Pan ZZ, Xie D, Kang TB, et al: Inhibition of the
NF-κB pathway by nafamostat mesilate suppresses colorectal cancer
growth and metastasis. Cancer Lett. 380:87–97. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xie C, Zhang LZ, Chen ZL, Zhong WJ, Fang
JH, Zhu Y, Xiao MH, Guo ZW, Zhao N, He X and Zhuang SM: A
hMTR4-PDIA3P1-miR-125/124-TRAF6 regulatory axis and its function in
NF kappa B signaling and chemoresistance. Hepatology. 71:1660–1677.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou L, Jiang Y, Luo Q, Li L and Jia L:
Neddylation: A novel modulator of the tumor microenvironment. Mol
Cancer. 18:772019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gamble C, McIntosh K, Scott R, Ho KH,
Plevin R and Paul A: Inhibitory kappa B Kinases as targets for
pharmacological regulation. Br J Pharmacol. 165:802–819. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Narayanan S, Cai CY, Assaraf YG, Guo HQ,
Cui Q, Wei L, Huang JJ, Ashby CR Jr and Chen ZS: Targeting the
ubiquitin-proteasome pathway to overcome anti-cancer drug
resistance. Drug Resist Updat. 48:1006632020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fiedler MA, Wernke-Dollries K and Stark
JM: Inhibition of TNF-alpha-induced NF-kappaB activation and IL-8
release in A549 cells with the proteasome inhibitor MG-132. Am J
Respir Cell Mol Biol. 19:259–268. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Winston JT, Strack P, Beer-Romero P, Chu
CY, Elledge SJ and Harper JW: The SCFbeta-TRCP-ubiquitin ligase
complex associates specifically with phosphorylated destruction
motifs in IkappaBalpha and beta-catenin and stimulates IkappaBalpha
ubiquitination in vitro. Genes Dev. 13:270–283. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhong W, Wu K, Long Z, Zhou X, Zhong C,
Wang S, Lai H, Guo Y, Lv D, Lu J and Mao X: Gut dysbiosis promotes
prostate cancer progression and docetaxel resistance via activating
NF-κB-IL6-STAT3 axis. Microbiome. 10:942022. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liang Y, Jiang Y, Jin X, Chen P, Heng Y,
Cai L, Zhang W, Li L and Jia L: Neddylation inhibition activates
the protective autophagy through NF-κB-catalase-ATF3 Axis in human
esophageal cancer cells. Cell Commun Signal. 18:722020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yaron A, Hatzubai A, Davis M, Lavon I,
Amit S, Manning AM, Andersen JS, Mann M, Mercurio F and Ben-Neriah
Y: Identi-fication of the receptor component of the
IkappaBalpha-ubiquitin ligase. Nature. 396:590–594. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tanaka T, Nakatani T and Kamitani T:
Inhibition of NEDD8-conjugation pathway by novel molecules:
Potential approaches to anticancer therapy. Mol Oncol. 6:267–275.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wang Z, Liu P, Inuzuka H and Wei W: Roles
of F-box proteins in cancer. Nat Rev Cancer. 14:233–247. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bi Y, Cui D, Xiong X and Zhao Y: The
characteristics and roles of β-TrCP1/2 in carcinogenesis. FEBS J.
288:3351–3374. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Koch A, Waha A, Hartmann W, Hrychyk A,
Schüller U, Waha A, Wharton KA Jr, Fuchs SY, von Schweinitz D and
Pietsch T: Elevated expression of Wnt antagonists is a common event
in hepatoblastomas. Clin Cancer Res. 11:4295–4304. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Perra A, Kowalik MA, Ghiso E,
Ledda-Columbano GM, Tommaso LD, Angioni MM, Raschioni C, Testore E,
Roncalli M, Giordano S and Columbano A: YAP activation is an early
event and a potential therapeutic target in liver cancer
development. J Hepatol. 61:1088–1096. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lu Y, Li X, Liu H, Xue J, Zeng Z, Dong X,
Zhang T, Wu G, Yang K and Xu S: β-Trcp and CK1δ-mediated
degradation of LZTS2 activates PI3K/AKT signaling to drive
tumorigenesis and metastasis in hepatocellular carcinoma. Oncogene.
40:1269–1283. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang YC, Wu YS, Hung CY, Wang SA, Young
MJ, Hsu TI and Hung JJ: USP24 induces IL-6 in tumor-associated
microenvironment by stabilizing p300 and beta-TrCP and promotes
cancer malignancy. Nat Commun. 9:39962018. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Peschiaroli A, Skaar JR, Pagano M and
Melino G: The ubiquitin-specific protease USP47 is a novel
beta-TRCP interactor regulating cell survival. Oncogene.
29:1384–1393. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bufalieri F, Infante P, Bernardi F,
Caimano M, Romania P, Moretti M, Severini LL, Talbot J, Melaiu O,
Tanori M, et al: ERAP1 promotes Hedgehog-dependent tumorigenesis by
controlling USP47-mediated degradation of betaTrCP. Nat Commun.
10:33042019. View Article : Google Scholar : PubMed/NCBI
|
